Urogen Pharma Ltd (URGN)

$46.31 -0.55 (-1.17%)
Market Cap 2.29B
Revenue (ttm) 109.79M
Net Income (ttm) -153.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -139.80%
Debt to Equity Ratio -1.43
Volume 523,884
Avg Vol 852,806
Day's Range N/A - N/A
Shares Out 48.88M
Stochastic %K 25%
Beta 1.57
Analysts Strong Sell
Price Target $60.00

Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
Mogeyman
Mogeyman Aug. 24 at 1:47 PM
$URGN Come on, go back up.
0 · Reply
ap20
ap20 Aug. 20 at 10:23 PM
$URGN They have experience in gel like medicines, so this to me seems like a decent shot at coming up with some new products at a not crazy price. I like it.
0 · Reply
ivocsev
ivocsev Aug. 20 at 3:47 PM
$URGN looks like a red day for bios all around. Still
1 · Reply
andrew_rovo
andrew_rovo Aug. 20 at 11:24 AM
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-announces-strategic-collaboration-and-investment
1 · Reply
STACKD0E
STACKD0E Aug. 20 at 11:12 AM
$ACIU $RADX $URGN $SHAZ 👁
0 · Reply
JamesTaulman
JamesTaulman Aug. 20 at 3:26 AM
WED 8/19: $URGN – BUYING (1/3) @ $50.40 3:44 PM – Initiating a 1/3 position in this Biotech stock near the close as shares display several bullish technical characteristics: (1) trading higher from near the 10 DMA, (2) breaking out above the ROUND-$50 level, and (3) trading on a massive 200% increase in volume. I cannot ignore this combination of bullish price-and-volume action, so I’m taking an initial position here. James’ Trader’s Tip: When the Evidence Stacks Up, Pay Attention • Advancing from the 10 DMA provides an initial sign of technical strength. • Breaking through a key resistance level adds further confirmation. • When those signals are accompanied by a massive increase in volume, the stock is clearly demanding attention. https://buyingbreakouts.com/wed-8-19-urgn-buying-1-3-50-40/
0 · Reply
BrunoGOudega
BrunoGOudega Aug. 19 at 7:12 PM
$URGN Getting selling fears. Been arround for 72 months and a 30% a year up.🫣
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 19 at 6:22 PM
$CGON $URGN *seen. I am always bullish on Urogen. Their CEO and Leadership is INCREDIBLE! $CGON … not so much 🤮
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 19 at 6:21 PM
$URGN best bladder cancer I ever seem, and I seen them all. $CGON is 🗑️ (trash) by comparison 💩
0 · Reply
rkd
rkd Aug. 19 at 3:56 PM
$URGN Should be picked off sooner rather than later. 3 fig BO. Extremely
1 · Reply
Latest News on URGN
IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

Aug 20, 2026, 7:05 AM EDT - 4 days ago

IntraGel Therapeutics and UroGen Pharma Sign Strategic Collaboration and Investment Agreements to Advance Sustained-Released Investigational Oncology Therapies

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

Aug 20, 2026, 7:00 AM EDT - 4 days ago

UroGen Announces Strategic Collaboration and Investment Agreements with IntraGel to Access Biodegradable Sustained-Release Gel Platform and Expand Oncology Pipeline

UroGen Pharma submits UGN-103 NDA to FDA

2026-08-17T12:11:24.000Z - 7 days ago

UroGen Pharma submits UGN-103 NDA to FDA

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

Aug 17, 2026, 8:00 AM EDT - 7 days ago

UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC

UroGen Pharma price target raised to $60 from $50 at Oppenheimer

2026-08-06T12:26:51.000Z - 18 days ago

UroGen Pharma price target raised to $60 from $50 at Oppenheimer

UroGen Pharma price target raised to $58 from $42 at Guggenheim

2026-08-06T10:54:52.000Z - 18 days ago

UroGen Pharma price target raised to $58 from $42 at Guggenheim

UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright

2026-08-06T10:11:56.000Z - 18 days ago

UroGen Pharma price target raised to $75 from $45 at H.C. Wainwright

UroGen Pharma price target raised to $60 from $50 at TD Cowen

2026-08-05T16:50:26.000Z - 19 days ago

UroGen Pharma price target raised to $60 from $50 at TD Cowen

UroGen Pharma Earnings Call Transcript: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 19 days ago

UroGen Pharma Earnings Call Transcript: Q2 2026

UroGen Pharma Earnings release: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 19 days ago

UroGen Pharma Earnings release: Q2 2026

UroGen Pharma Quarterly report: Q2 2026

Aug 5, 2026, 10:00 AM EDT - 19 days ago

UroGen Pharma Quarterly report: Q2 2026

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

Aug 5, 2026, 8:00 AM EDT - 19 days ago

UroGen Reports $50.4 Million of ZUSDURI Revenue and Provides Second Quarter 2026 Financial Results and Highlights

UroGen Pharma Slides: Corporate presentation

Aug 4, 2026, 7:00 AM EDT - 20 days ago

UroGen Pharma Slides: Corporate presentation

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

Jul 29, 2026, 8:00 AM EDT - 26 days ago

UroGen Pharma to Report Second Quarter 2026 Financial Results on Wednesday, August 5th, 2026

UroGen Pharma price target raised to $42 from $32 at Guggenheim

2026-07-21T12:06:30.000Z - 4 weeks ago

UroGen Pharma price target raised to $42 from $32 at Guggenheim

UroGen Pharma price target raised to $50 from $40 at Oppenheimer

2026-07-16T12:21:41.000Z - 5 weeks ago

UroGen Pharma price target raised to $50 from $40 at Oppenheimer

UroGen Pharma price target raised to $44 from $18 at Goldman Sachs

2026-07-15T21:15:11.000Z - 5 weeks ago

UroGen Pharma price target raised to $44 from $18 at Goldman Sachs

UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103

2026-07-15T21:10:12.000Z - 5 weeks ago

UroGen Pharma gets new US patent allowance into July 2044 for ZUSDURI, UGN-103

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

Jul 15, 2026, 8:00 AM EDT - 5 weeks ago

UroGen Receives New U.S. Patent Allowance Expected to Provide Protection into July 2044 for ZUSDURI™ and UGN-103

UroGen Pharma announces FDA clearance for UGN-501 IND application

2026-07-08T12:05:46.000Z - 6 weeks ago

UroGen Pharma announces FDA clearance for UGN-501 IND application

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

Jul 8, 2026, 8:00 AM EDT - 6 weeks ago

UroGen Announces FDA Clearance of the IND for UGN-501, an Investigational Next-Generation Oncolytic Virus for Non-Muscle Invasive Bladder Cancer

UroGen Pharma Transcript: AGM 2026

Jun 22, 2026, 10:00 AM EDT - 2 months ago

UroGen Pharma Transcript: AGM 2026

UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

Jun 10, 2026, 8:40 AM EDT - 2 months ago

UroGen Pharma Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jun 5, 2026, 8:00 AM EDT - 2 months ago

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

Jun 2, 2026, 8:00 AM EDT - 2 months ago

UroGen Announces Agreement Resolving Patent Litigation Relating to JELMYTO® (mitomycin) for pyelocalyceal solution

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

Jun 1, 2026, 4:10 PM EDT - 2 months ago

UroGen Pharma to Present at the Goldman Sachs 47th Annual Global Healthcare Conference

UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

May 26, 2026, 10:30 AM EDT - 3 months ago

UroGen Pharma Transcript: 7th Annual Oncology Innovation Summit: Insights for ASCO & EHA

UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

May 19, 2026, 10:30 AM EDT - 3 months ago

UroGen Pharma Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference

UroGen Pharma reports month results from UTOPIA trial

2026-05-15T15:46:42.000Z - 3 months ago

UroGen Pharma reports month results from UTOPIA trial

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

May 15, 2026, 8:00 AM EDT - 3 months ago

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 11:15 AM EDT - 3 months ago

UroGen Pharma Transcript: Bank of America Global Healthcare Conference 2026

UroGen Pharma presents 36-month ENVISION trial data

2026-05-13T14:22:11.000Z - 3 months ago

UroGen Pharma presents 36-month ENVISION trial data

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

May 13, 2026, 8:00 AM EDT - 3 months ago

ZUSDURI Median Duration of Response Still Not Reached with 64.5% 36-month Duration of Response in the Pivotal ENVISION Trial

UroGen Pharma assumed with a Buy at Ladenburg

2026-05-11T15:30:55.000Z - 3 months ago

UroGen Pharma assumed with a Buy at Ladenburg

UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright

2026-05-11T10:34:38.000Z - 3 months ago

UroGen Pharma price target raised to $45 from $40 at H.C. Wainwright

UroGen Pharma price target raised to $40 from $34 at Oppenheimer

2026-05-07T14:34:00.000Z - 3 months ago

UroGen Pharma price target raised to $40 from $34 at Oppenheimer

UroGen Pharma to Present at Upcoming Investor Conferences

May 7, 2026, 8:00 AM EDT - 3 months ago

UroGen Pharma to Present at Upcoming Investor Conferences

UroGen Pharma reports Q1 EPS (47c), consensus (36c)

2026-05-07T03:46:46.000Z - 3 months ago

UroGen Pharma reports Q1 EPS (47c), consensus (36c)

UroGen Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Earnings Call Transcript: Q1 2026

UroGen Pharma Earnings release: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Earnings release: Q1 2026

UroGen Pharma Quarterly report: Q1 2026

May 6, 2026, 10:00 AM EDT - 3 months ago

UroGen Pharma Quarterly report: Q1 2026

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

May 6, 2026, 8:00 AM EDT - 3 months ago

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 4 months ago

UroGen Pharma Proxy statement: Proxy filing

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

Apr 29, 2026, 8:00 AM EDT - 4 months ago

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

UroGen Pharma Proxy statement: Proxy filing

Apr 17, 2026, 8:00 AM EDT - 4 months ago

UroGen Pharma Proxy statement: Proxy filing

UroGen Pharma initiated with a Buy at Jefferies

2026-04-09T20:26:32.000Z - 4 months ago

UroGen Pharma initiated with a Buy at Jefferies

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Apr 8, 2026, 8:00 AM EDT - 4 months ago

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

UroGen Pharma publishes results from ENVISION trial of Zusduri

2026-03-30T13:09:37.000Z - 5 months ago

UroGen Pharma publishes results from ENVISION trial of Zusduri

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report

2026-03-13T12:16:20.000Z - 5 months ago

UroGen Pharma ‘commends’ BCAN release of Bladder Cancer Report

UroGen Pharma Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 1:50 PM EST - 6 months ago

UroGen Pharma Transcript: TD Cowen 46th Annual Health Care Conference

UroGen Pharma Earnings Call Transcript: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Earnings Call Transcript: Q4 2025

UroGen Pharma Annual report: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Annual report: Q4 2025

UroGen Pharma Earnings release: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Earnings release: Q4 2025

UroGen Pharma Annual report: Q4 2025

Mar 2, 2026, 10:00 AM EST - 6 months ago

UroGen Pharma Annual report: Q4 2025

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

Mar 2, 2026, 8:00 AM EST - 6 months ago

UroGen Announces ZUSDURI™ Launch is On-Track and Reports Fourth Quarter and Full Year 2025 Financial Results

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

Mar 2, 2026, 7:55 AM EST - 6 months ago

UroGen Announces Refinanced Term Loan Agreement with Pharmakon Advisors

UroGen Pharma Slides: Corporate presentation

Mar 2, 2026, 7:00 AM EST - 6 months ago

UroGen Pharma Slides: Corporate presentation

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

Feb 27, 2026, 8:30 AM EST - 6 months ago

ZUSDURI™ Achieves Durable Complete Responses Across EORTC Risk Groups in Patients with Recurrent LG-IR-NMIBC

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

Feb 24, 2026, 4:05 PM EST - 6 months ago

UroGen Pharma to Present at the TD Cowen 46th Annual Health Care Conference

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

Feb 23, 2026, 8:00 AM EST - 6 months ago

UroGen Pharma to Report Fourth Quarter and Full-Year 2025 Financial Results on Monday, March 2, 2026

UroGen Pharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

Feb 12, 2026, 2:30 PM EST - 6 months ago

UroGen Pharma Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

Feb 4, 2026, 8:00 AM EST - 7 months ago

UroGen Pharma to Present at the Guggenheim Securities Emerging Outlook: Biotech Summit

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

Jan 5, 2026, 8:00 AM EST - 8 months ago

Permanent J Code for ZUSDURI™ Now in Effect, Expanding Patient Access to Innovative Bladder Cancer Therapy

UroGen Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 2, 2025, 1:00 PM EST - 9 months ago

UroGen Pharma Transcript: Piper Sandler 37th Annual Healthcare Conference

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

Nov 25, 2025, 8:00 AM EST - 9 months ago

UroGen Pharma to Present at the Piper Sandler 37th Annual Healthcare Conference

UroGen Pharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

Nov 11, 2025, 10:30 AM EST - 10 months ago

UroGen Pharma Transcript: Guggenheim Securities 2nd Annual Healthcare Innovation Conference

UroGen Pharma Earnings Call Transcript: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Earnings Call Transcript: Q3 2025

UroGen Pharma Quarterly report: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Quarterly report: Q3 2025

UroGen Pharma Earnings release: Q3 2025

Nov 6, 2025, 10:00 AM EST - 10 months ago

UroGen Pharma Earnings release: Q3 2025

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

Nov 6, 2025, 8:00 AM EST - 10 months ago

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI™ Launch Gains Momentum

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

Nov 6, 2025, 7:58 AM EST - 10 months ago

UroGen Reports 77.8% Three-Month Complete Response Rate from Phase 3 UTOPIA Trial of UGN-103 and Receives FDA Agreement on NDA Submission Strategy in Recurrent LG-IR-NMIBC Based on UTOPIA Trial

UroGen Pharma Slides: Corporate Presentation

Nov 4, 2025, 6:00 PM EST - 10 months ago

UroGen Pharma Slides: Corporate Presentation

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

Nov 4, 2025, 8:00 AM EST - 10 months ago

UroGen Pharma to Present at Guggenheim Securities Healthcare Innovation Conference

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Oct 30, 2025, 8:00 AM EDT - 10 months ago

UroGen Pharma to Report Third Quarter 2025 Financial Results on Thursday, November 6th, 2025

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

Oct 27, 2025, 8:00 AM EDT - 10 months ago

Centers for Medicare and Medicaid Services Assigns Permanent J Code for ZUSDURI™ Effective January 1, 2026

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Oct 2, 2025, 8:00 AM EDT - 11 months ago

ZUSDURI™ Clinical Review Published in Reviews in Urology™ Highlights Durable Efficacy and Manageable Safety Profile in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

UroGen Pharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Sep 8, 2025, 9:00 AM EDT - 1 year ago

UroGen Pharma Transcript: H.C. Wainwright 27th Annual Global Investment Conference

UroGen Pharma Transcript: Cantor Global Healthcare Conference 2025

Sep 4, 2025, 3:55 PM EDT - 1 year ago

UroGen Pharma Transcript: Cantor Global Healthcare Conference 2025

UroGen Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

Sep 3, 2025, 2:15 PM EDT - 1 year ago

UroGen Pharma Transcript: Wells Fargo 20th Annual Healthcare Conference 2025

UroGen Pharma Transcript: AGM 2025

Aug 26, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Transcript: AGM 2025

UroGen Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Earnings Call Transcript: Q2 2025

UroGen Pharma Quarterly report: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Quarterly report: Q2 2025

UroGen Pharma Earnings release: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 1 year ago

UroGen Pharma Earnings release: Q2 2025

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 8:00 AM EDT - 1 year ago

UroGen Pharma Expands Commercial Portfolio with Launch of ZUSDURI™ and Reports Second Quarter 2025 Financial Results

UroGen Pharma Slides: Corporate Presentation

Aug 7, 2025, 7:00 AM EDT - 1 year ago

UroGen Pharma Slides: Corporate Presentation

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Aug 5, 2025, 8:00 AM EDT - 1 year ago

UroGen Announces 24-Month Duration of Response of 72.2% from the Pivotal Phase 3 ENVISION Trial of ZUSDURI, the First and Only FDA-Approved Medicine for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

Jul 29, 2025, 8:00 AM EDT - 1 year ago

UroGen Pharma to Report Second Quarter 2025 Financial Results on Thursday, August 7th, 2025

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

Jul 28, 2025, 8:00 AM EDT - 1 year ago

UroGen Announces Publication of Phase 3b Study Results Demonstrating the Feasibility of Home Instillation of ZUSDURI™ for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer in Reviews in Urology

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 21, 2025, 8:00 AM EDT - 1 year ago

UroGen Announces Five-Year Long-Term Extension Study of the OPTIMA II Trial Demonstrates Long-Term Durability of Response to ZUSDURI™ in Patients with Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Proxy statement: Proxy Filing

Jul 15, 2025, 8:00 AM EDT - 1 year ago

UroGen Pharma Proxy statement: Proxy Filing

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

Jul 7, 2025, 8:00 AM EDT - 1 year ago

UroGen Announces Completion of Enrollment in the Phase 3 UTOPIA Clinical Trial of UGN-103 for the Treatment of Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Slides: Corporate Presentation

Jun 17, 2025, 7:00 AM EDT - 1 year ago

UroGen Pharma Slides: Corporate Presentation

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

Jun 16, 2025, 8:17 AM EDT - 1 year ago

URGN SHAREHOLDER REPORT: UroGen Pharma Ltd. was Sued for Fraud – Investors with Losses are Notified to Contact BFA Law by July 28 Court Deadline (NASDAQ:URGN)

UroGen Pharma Transcript: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Transcript: Study Update

UroGen Pharma Press release: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Press release: Study Update

UroGen Pharma Slides: Study Update

Jun 13, 2025, 8:30 AM EDT - 1 year ago

UroGen Pharma Slides: Study Update

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Jun 12, 2025, 1:28 PM EDT - 1 year ago

U.S. FDA Approves UroGen's ZUSDURI™ (mitomycin) for Intravesical Solution as the First and Only Medication for Recurrent Low-Grade Intermediate-Risk Non-Muscle Invasive Bladder Cancer (LG-IR-NMIBC)

Mogeyman
Mogeyman Aug. 24 at 1:47 PM
$URGN Come on, go back up.
0 · Reply
ap20
ap20 Aug. 20 at 10:23 PM
$URGN They have experience in gel like medicines, so this to me seems like a decent shot at coming up with some new products at a not crazy price. I like it.
0 · Reply
ivocsev
ivocsev Aug. 20 at 3:47 PM
$URGN looks like a red day for bios all around. Still
1 · Reply
andrew_rovo
andrew_rovo Aug. 20 at 11:24 AM
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-announces-strategic-collaboration-and-investment
1 · Reply
STACKD0E
STACKD0E Aug. 20 at 11:12 AM
$ACIU $RADX $URGN $SHAZ 👁
0 · Reply
JamesTaulman
JamesTaulman Aug. 20 at 3:26 AM
WED 8/19: $URGN – BUYING (1/3) @ $50.40 3:44 PM – Initiating a 1/3 position in this Biotech stock near the close as shares display several bullish technical characteristics: (1) trading higher from near the 10 DMA, (2) breaking out above the ROUND-$50 level, and (3) trading on a massive 200% increase in volume. I cannot ignore this combination of bullish price-and-volume action, so I’m taking an initial position here. James’ Trader’s Tip: When the Evidence Stacks Up, Pay Attention • Advancing from the 10 DMA provides an initial sign of technical strength. • Breaking through a key resistance level adds further confirmation. • When those signals are accompanied by a massive increase in volume, the stock is clearly demanding attention. https://buyingbreakouts.com/wed-8-19-urgn-buying-1-3-50-40/
0 · Reply
BrunoGOudega
BrunoGOudega Aug. 19 at 7:12 PM
$URGN Getting selling fears. Been arround for 72 months and a 30% a year up.🫣
1 · Reply
JuggernautRaider
JuggernautRaider Aug. 19 at 6:22 PM
$CGON $URGN *seen. I am always bullish on Urogen. Their CEO and Leadership is INCREDIBLE! $CGON … not so much 🤮
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 19 at 6:21 PM
$URGN best bladder cancer I ever seem, and I seen them all. $CGON is 🗑️ (trash) by comparison 💩
0 · Reply
rkd
rkd Aug. 19 at 3:56 PM
$URGN Should be picked off sooner rather than later. 3 fig BO. Extremely
1 · Reply
ivocsev
ivocsev Aug. 18 at 11:51 AM
$URGN
1 · Reply
LewisDaKat
LewisDaKat Aug. 17 at 7:30 PM
$URGN UroGen Submits NDA for UGN-103, an Investigational Treatment of Recurrent LG-IR-NMIBC https://marketwirenews.com/stock/urgn/news/urogen-submits-nda-for-ugn-103-an-investigational-tr-5828805966855917.html?utm_source=stocktwits
0 · Reply
Pukkaa56
Pukkaa56 Aug. 17 at 6:27 PM
$URGN Up to $50
0 · Reply
Mogeyman
Mogeyman Aug. 17 at 1:50 PM
$URGN Let's see how this goes. With how big the 2Q ER was, I imagine 3Q is going to be even better.
0 · Reply
andrew_rovo
andrew_rovo Aug. 17 at 1:24 PM
$URGN https://investors.urogen.com/news-releases/news-release-details/urogen-submits-nda-ugn-103-investigational-treatment-recurrent
0 · Reply
Mogeyman
Mogeyman Aug. 14 at 8:39 PM
$URGN Will be loading up next week when funds clear. Not waiting for a dip.
0 · Reply
TheBehavioralTrader
TheBehavioralTrader Aug. 12 at 11:00 PM
$MGNI $PAYS $URGN All three of these symbols have the same behavioral pattern all three were alerted today for members StockreversalsPremium.com
1 · Reply
Mogeyman
Mogeyman Aug. 12 at 8:52 PM
$URGN This thing is a monster 2Q ER was awesome, I imagine 3Q will be another banger.
0 · Reply
WAJeff
WAJeff Aug. 12 at 7:17 PM
$URGN 49.67 52 week high
0 · Reply
MaverikIT
MaverikIT Aug. 12 at 6:59 PM
$ATRC $NRIX $URGN new 52wk$ today
0 · Reply
MaverikIT
MaverikIT Aug. 12 at 2:16 PM
$AEHR $URGN @BustaCapital @Jblack500 @cynicaloptimist @IsabellaDC @WAJeff @No_Face_character
0 · Reply
chickenboy
chickenboy Aug. 11 at 10:12 PM
$URGN Short interest has plunged to 4.589M shares as of 7/31/26, almost a 20% drop since the 7/15/26 report. Wishing I had bought more shares in the $30's. GLTA.
1 · Reply